Knight Therapeutics (KHTRF) 6.7000 $KHTRF
Knight Therapeutics Inc. Broadens Its Innovative Pharmaceutical Product Sourcing Strategy
Marketwired - Fri Apr 03, 9:01AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"
, a leading Canadian specialty pharmaceutical company, announced today that it has committed to invest $10 million in HarbourVest Canada Growth Fund. L.P. ("HarbourVest Fund". This investment is consistent with Knight's strategy to leverage proven life science funds to help secure innovative pharmaceuticals for Canada and select international markets. Similar to the Teralys Capital Innovation Fund LP, the HarbourVest Fund is part of the Government of Canada's Venture Capital Action Plan.
GUD.TO: 8.36 (+0.09)
Knight Therapeutics Participates in Secured Debt Offering
Marketwired - Tue Mar 31, 7:04AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company", a leading Canadian specialty pharmaceutical company, announced today that it has participated in the secured convertible debenture ("Debentures" financing of Pediapharm Inc. (TSX VENTURE: PDP) ("Pediapharm".
PDP.VN: 0.325 (-0.005), GUD.TO: 8.36 (+0.09)
Knight Therapeutics' Secured Lending Strategy Validated by CRH Medical Corporation
Marketwired - Wed Mar 25, 5:04PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company", a leading Canadian specialty pharmaceutical company, announced today that it successfully helped finance CRH Medical Corporation's (TSX: CRH) (OTCQX: CRMMF) ("CRH" U.S. expansion as best evidenced by CRH's recent equity offering: CRH raised $27.37 million of equity at $3.40 per share, more than triple the share price from when Knight extended the secured loan less than four months ago, in the public markets and is using such proceeds to retire USD$7.9 million of its secured debt to Knight. CRH is a North American medical company focused on providing physicians with innovative products and services for the treatment of gastrointestinal diseases.
CRH.TO: 3.99 (+0.36), GUD.TO: 8.36 (+0.09)
Knight Reports Fourth Quarter and Year Ended December 31, 2014 Results
Marketwired - Thu Mar 19, 5:01AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company", a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2014.
GUD.TO: 8.36 (+0.09)
Notice of Knight Therapeutics' Fourth Quarter and Year Ended December 31, 2014 Results Conference Call
Marketwired - Thu Mar 12, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight", a leading Canadian specialty pharmaceutical company, will release its fourth quarter and year ended December 31, 2014 financial results on Thursday, March 19, 2015 prior to the market opening. Following the release, Knight will hold a conference call at 8:30 a.m. (EST) hosted by Jonathan Goodman, President and CEO of Knight. Knight cordially invites all interested parties to participate in this call.
GUD.TO: 8.36 (+0.09)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 4.17 (-0.06), TRIL: 28.73 (-0.36)
Knight Therapeutics: Minimal Downside For This Misunderstood Company
Understanding Businesses - at Seeking Alpha - Thu Jan 29, 1:06PM CST
Synergy Strips Corp. Acquires Assets of America's No.1 Brain Health Supplement, FOCUSfactor
Business Wire - Mon Jan 26, 4:25PM CST
Synergy Strips Corp. (OTCQB:SNYR) ("Synergy", a company that markets and distributes consumer products primarily in the health and wellness industry, today announced the acquisition of the FOCUSfactor(R) brand, America's No.1 brain health supplement, from Factor Nutrition Labs, LLC. Knight Therapeutics Inc. (TSX:GUD), through one of its wholly owned subsidiaries ("Knight", financed the transaction with a $6 million secured loan. FOCUSfactor is sold at retail stores including Costco, Sam's Club, Walmart, Walgreens, CVS and The Vitamin Shoppe.
VSI: 40.55 (-0.01), GUD.TO: 8.36 (+0.09)
Knight Therapeutics Inc. Signs Secured Debt Financing Agreement
Marketwired - Thu Jan 22, 4:01PM CST
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly owned subsidiaries ("Knight", announced today that it has entered into a senior secured debt financing agreement with Synergy Strips Corp. (OTCQB: SNYR) ("Synergy", a US company focused on the health and wellness sector. The secured loan will fund Synergy's acquisition of the FOCUSfactor brand, the United States' #1 brain health supplement.
GUD.TO: 8.36 (+0.09)
Knight Therapeutics Inc. Announces Board Change
Marketwired - Wed Jan 21, 4:01PM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight" announced today (i) the resignation of Hillel Rosen and (ii) the appointment Ed Schutter to Knight's Board of Directors. "Hillel will continue to provide legal counsel to Knight and its Board, and we thank him for his contributions to date," said Jonathan Ross Goodman, President and CEO of Knight. "In his place, we welcome Ed Schutter, founder and CEO of US specialty pharmaceutical Arbor Pharmaceuticals, LLC., to our leadership team. Ed is a proven pharmaceutical entrepreneur."
GUD.TO: 8.36 (+0.09)
Knight Therapeutics Inc. and NeurAxon Inc. Form Partnership for the Commercialization of NeurAxon's Innovative Products
Marketwired - Thu Jan 01, 7:01AM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company", a leading Canadian specialty pharmaceutical company, today announced that it has entered into a strategic partnership with NeurAxon Inc. ("NeurAxon" for the commercialization of NeurAxon's innovative products in various stages of development ("Pharmaceuticals" in Canada, Israel, South Africa and Russia ("Territory".
GUD.TO: 8.36 (+0.09)
Knight Further Executes Its Innovative Pharmaceutical Product Sourcing Strategy
Marketwired - Tue Dec 16, 7:04AM CST
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly owned subsidiaries ("Knight", announced today that it has committed to invest US$25 million into Domain Partners IX, L.P. ("Domain Fund" and US$10 million in Sanderling Ventures VII, L.P. ("Sanderling Fund". These investments into proven successful life science funds complement Knight Therapeutics Inc.'s US$13 million investment in Sectoral, EUREUR19.5 million investment in Forbion, and CAD$30 million investment in Teralys. These five funds have combined assets under management in healthcare of approximately CAD$9 billion.
GUD.TO: 8.36 (+0.09)
Knight Therapeutics Inc. Broadens Its Innovative Pharmaceutical Product Sourcing Strategy
Marketwired - Fri Apr 03, 9:01AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"
, a leading Canadian specialty pharmaceutical company, announced today that it has committed to invest $10 million in HarbourVest Canada Growth Fund. L.P. ("HarbourVest Fund". This investment is consistent with Knight's strategy to leverage proven life science funds to help secure innovative pharmaceuticals for Canada and select international markets. Similar to the Teralys Capital Innovation Fund LP, the HarbourVest Fund is part of the Government of Canada's Venture Capital Action Plan. GUD.TO: 8.36 (+0.09)
Knight Therapeutics Participates in Secured Debt Offering
Marketwired - Tue Mar 31, 7:04AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"
, a leading Canadian specialty pharmaceutical company, announced today that it has participated in the secured convertible debenture ("Debentures" financing of Pediapharm Inc. (TSX VENTURE: PDP) ("Pediapharm". PDP.VN: 0.325 (-0.005), GUD.TO: 8.36 (+0.09)
Knight Therapeutics' Secured Lending Strategy Validated by CRH Medical Corporation
Marketwired - Wed Mar 25, 5:04PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"
, a leading Canadian specialty pharmaceutical company, announced today that it successfully helped finance CRH Medical Corporation's (TSX: CRH) (OTCQX: CRMMF) ("CRH" U.S. expansion as best evidenced by CRH's recent equity offering: CRH raised $27.37 million of equity at $3.40 per share, more than triple the share price from when Knight extended the secured loan less than four months ago, in the public markets and is using such proceeds to retire USD$7.9 million of its secured debt to Knight. CRH is a North American medical company focused on providing physicians with innovative products and services for the treatment of gastrointestinal diseases. CRH.TO: 3.99 (+0.36), GUD.TO: 8.36 (+0.09)
Knight Reports Fourth Quarter and Year Ended December 31, 2014 Results
Marketwired - Thu Mar 19, 5:01AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"
, a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2014. GUD.TO: 8.36 (+0.09)
Notice of Knight Therapeutics' Fourth Quarter and Year Ended December 31, 2014 Results Conference Call
Marketwired - Thu Mar 12, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"
, a leading Canadian specialty pharmaceutical company, will release its fourth quarter and year ended December 31, 2014 financial results on Thursday, March 19, 2015 prior to the market opening. Following the release, Knight will hold a conference call at 8:30 a.m. (EST) hosted by Jonathan Goodman, President and CEO of Knight. Knight cordially invites all interested parties to participate in this call. GUD.TO: 8.36 (+0.09)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 4.17 (-0.06), TRIL: 28.73 (-0.36)
Knight Therapeutics: Minimal Downside For This Misunderstood Company
Understanding Businesses - at Seeking Alpha - Thu Jan 29, 1:06PM CST
Synergy Strips Corp. Acquires Assets of America's No.1 Brain Health Supplement, FOCUSfactor
Business Wire - Mon Jan 26, 4:25PM CST
Synergy Strips Corp. (OTCQB:SNYR) ("Synergy"
, a company that markets and distributes consumer products primarily in the health and wellness industry, today announced the acquisition of the FOCUSfactor(R) brand, America's No.1 brain health supplement, from Factor Nutrition Labs, LLC. Knight Therapeutics Inc. (TSX:GUD), through one of its wholly owned subsidiaries ("Knight", financed the transaction with a $6 million secured loan. FOCUSfactor is sold at retail stores including Costco, Sam's Club, Walmart, Walgreens, CVS and The Vitamin Shoppe. VSI: 40.55 (-0.01), GUD.TO: 8.36 (+0.09)
Knight Therapeutics Inc. Signs Secured Debt Financing Agreement
Marketwired - Thu Jan 22, 4:01PM CST
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly owned subsidiaries ("Knight"
, announced today that it has entered into a senior secured debt financing agreement with Synergy Strips Corp. (OTCQB: SNYR) ("Synergy", a US company focused on the health and wellness sector. The secured loan will fund Synergy's acquisition of the FOCUSfactor brand, the United States' #1 brain health supplement. GUD.TO: 8.36 (+0.09)
Knight Therapeutics Inc. Announces Board Change
Marketwired - Wed Jan 21, 4:01PM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight"
announced today (i) the resignation of Hillel Rosen and (ii) the appointment Ed Schutter to Knight's Board of Directors. "Hillel will continue to provide legal counsel to Knight and its Board, and we thank him for his contributions to date," said Jonathan Ross Goodman, President and CEO of Knight. "In his place, we welcome Ed Schutter, founder and CEO of US specialty pharmaceutical Arbor Pharmaceuticals, LLC., to our leadership team. Ed is a proven pharmaceutical entrepreneur." GUD.TO: 8.36 (+0.09)
Knight Therapeutics Inc. and NeurAxon Inc. Form Partnership for the Commercialization of NeurAxon's Innovative Products
Marketwired - Thu Jan 01, 7:01AM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"
, a leading Canadian specialty pharmaceutical company, today announced that it has entered into a strategic partnership with NeurAxon Inc. ("NeurAxon" for the commercialization of NeurAxon's innovative products in various stages of development ("Pharmaceuticals" in Canada, Israel, South Africa and Russia ("Territory". GUD.TO: 8.36 (+0.09)
Knight Further Executes Its Innovative Pharmaceutical Product Sourcing Strategy
Marketwired - Tue Dec 16, 7:04AM CST
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly owned subsidiaries ("Knight"
, announced today that it has committed to invest US$25 million into Domain Partners IX, L.P. ("Domain Fund" and US$10 million in Sanderling Ventures VII, L.P. ("Sanderling Fund". These investments into proven successful life science funds complement Knight Therapeutics Inc.'s US$13 million investment in Sectoral, EUREUR19.5 million investment in Forbion, and CAD$30 million investment in Teralys. These five funds have combined assets under management in healthcare of approximately CAD$9 billion. GUD.TO: 8.36 (+0.09)
